Management Strategies for Small-for-Size Syndrome in Living Donor Liver Transplantation

Overview

Small-for-size syndrome (SFSS) is a critical complication in living donor liver transplantation (LDLT) characterized by graft dysfunction due to insufficient liver mass and portal hyperperfusion. This review highlights the pathophysiology, risk factors including graft size and quality, and strategies such as graft inflow modulation to mitigate SFSS.

Background

SFSS was first identified in 1999 as a complication associated with graft-to-recipient weight ratios (GRWR) below 1%, leading to poor graft survival. It manifests clinically with hyperbilirubinemia, coagulopathy, encephalopathy, and refractory ascites, potentially progressing to liver failure and death. The syndrome results from excessive portal vein flow causing sinusoidal injury and hepatic artery vasoconstriction due to the hepatic arterial buffer response. Both unmodifiable factors like graft size and donor age, and modifiable factors such as graft inflow, contribute to SFSS risk.

Data Highlights

Key Findings

• SFSS results from excessive portal vein flow causing sinusoidal injury and hepatic artery vasoconstriction via the hepatic arterial buffer response.
• Graft size is a major risk factor; GRWR below 0.8–1% or graft/SLV ratio below 40% significantly increases SFSS risk.
• Donor factors such as age over 45 years and graft steatosis (above 10–20%) contribute to SFSS development.
• Recipient factors including high MELD score (>20), poor functional reserve, and ICU or dialysis status at transplant increase SFSS risk.
• Hemodynamic monitoring using direct methods like transit time ultrasonic flowmeters and non-invasive ultrasound is critical for managing graft inflow and preventing SFSS.
• Graft inflow modulation and management of portosystemic shunts are key strategies to mitigate SFSS occurrence and severity.

Clinical Implications

Clinicians should carefully assess donor and recipient risk factors including graft size, donor age, and graft steatosis before LDLT to minimize SFSS risk. Intraoperative hemodynamic monitoring and graft inflow modulation are essential to optimize portal vein flow and hepatic artery perfusion. Tailored strategies based on these parameters can improve graft survival and patient outcomes.

Conclusion

SFSS remains a significant challenge in LDLT, driven by complex hemodynamic and graft-related factors. Understanding its pathophysiology and risk factors enables targeted interventions such as graft inflow modulation to improve transplant success.

References

1. Kiuchi et al. 1999 -- First report on small-for-size grafts in LDLT
2. Bhangui et al. -- Safety thresholds for graft steatosis in living donation
3. Additional sources cited in review